Latest news with #clinicians
Medscape
a day ago
- Health
- Medscape
Rotator Cuff Tendinopathy Clinical Practice Guidelines (2025)
Editorial Note: These are some of the highlights of the guidelines without analysis or commentary. For more information, go directly to the guidelines by clicking the link in the reference. Clinical practice guidelines on the diagnosis and treatment of adults with rotator cuff tendinopathy were published in April 2025 in the Journal of Orthopaedic & Sports Physical Therapy.[1] In place of visual estimation, an inclinometer, a goniometer, or a smartphone inclinometer/goniometer application should be employed by clinicians in the objective measurement of active and passive range of motion (ROM) of the shoulder. The unreliability and limited validity of scapular ROM measures mean that they 'should not be used by clinicians to objectively measure dynamic scapular ROM.' Oral nonsteroidal anti-inflammatory drugs (NSAIDs) may be recommended by clinicians for short-term pain reduction in adults with rotator cuff tendinopathy. An active rehabilitation exercise program should be prescribed or recommended by clinicians as an initial treatment for pain and disability reduction in adults with rotator cuff tendinopathy. This 'may include motor control and/or resistance training exercises with various loads.' To aid in short-term pain reduction in adults with rotator cuff tendinopathy, spinal and/or upper limb manual therapy can be employed either by themselves 'or in combination with other interventions such as exercise.' Soft tissue techniques and/or joint mobilizations or manipulations can be included in manual therapy. In adults with rotator cuff noncalcific tendinopathy, therapeutic ultrasound should not be used (or recommended for use) as a means of pain and disability reduction, either alone or in combination with an active rehabilitation program. For more information, please go to Rotator Cuff Disease, Rotator Cuff Injury, and Rotator Cuff Pathology.
Yahoo
2 days ago
- Business
- Yahoo
FeNO Breathing Monitors Market Global Forecast to 2030, Featuring Bedfont Scientific, Bosch Healthcare Solutions, CAIRE, COSMED, e-LinkCare Meditech, ECO MEDICS, MGC Diagnostics, NIOX and Vitalograph
Key market opportunities for FeNO breathing monitors include the integration with telehealth and homecare models, driven by technological advancements and reduced device costs. With rising demand for personalized respiratory care, leveraging sensor innovations and aligning with clinical guidelines will be essential to capturing growth in this evolving market. FeNO Breathing Monitors Market Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "FeNO Breathing Monitors Market by Technology, Patient Age Group, Warning Signal, Distribution Channel, Application, End User - Global Forecast to 2030" has been added to offering. The FeNO Breathing Monitors Market has demonstrated substantial growth, with its size expanding from USD 275.95 million in 2024 to USD 303.10 million in 2025, and is projected to reach USD 490.87 million by 2030. As a critical tool in respiratory care, FeNO breathing monitors empower clinicians and patients by providing precise measurements of fractional exhaled nitric oxide, facilitating improved clinical decision-making and personalized therapy adjustments. The increasing adoption across various healthcare environments underscores the technology's transformative potential in managing chronic respiratory diseases. Key Technological and Clinical Transformations FeNO breathing monitors are experiencing rapid advancements due to innovations in sensor technology and clinical practice changes. Sensor chemistry and miniaturization progress have reduced costs and enhanced portability, supporting their integration into smartphone-linked platforms and remote monitoring systems. Such developments enhance the appeal of home-based care models and telehealth services, which are now playing a more significant role in respiratory disease management. Additionally, clinical guidelines recognizing exhaled nitric oxide as an essential biomarker for inflammation in asthma and respiratory conditions have propelled the demand for FeNO monitoring among healthcare providers. This demand is driven by improved patient outcomes and cost savings linked with routine monitoring, aiding in strategic planning and competitive advantage for organizations in this field. Evaluating the Strategic Consequences of 2025 US Sensor Tariffs The introduction of new tariffs on imported medical sensors in 2025 has introduced challenges within the FeNO monitor ecosystem. The increased duties on components like sensor substrates and proprietary reagent kits have required manufacturers to reassess their cost structures and sourcing strategies. Some industry players are exploring domestic supply sources, while others incorporate new revenue models to offset tariff-induced costs. This situation highlights the need for agility in procurement and manufacturing strategies to maintain competitive pricing and mitigate risks associated with evolving trade policies. Key Takeaways from This Report This report identifies the convergence of technological innovations and evolving clinical guidelines as critical growth drivers for FeNO breathing monitors. Stakeholders can leverage these advancements for strategic planning and improving competitive edge. The adaptive responses to tariff challenges also illustrate the importance of agile procurement strategies in maintaining market positioning. Extensive segmentation analysis across technology, patient demographics, distribution channels, and application provides nuanced insights, enabling identification of market entry strategies and opportunities for growth. Nuanced Segmentation Insights Market segmentation reveals distinct characteristics among technology types, patient demographics, and application domains. Chemiluminescence sensors remain favored in research and hospital settings for their high sensitivity, while electrochemical sensors dominate homecare for their cost efficiency. Pediatric devices must accommodate gentle interfaces and intuitive designs to ensure reliable usage. Moreover, distribution strategies vary between offline channels with established supply chains and online channels that enhance direct consumer engagement. A thorough understanding of these segments allows for customization of value propositions to resonate with targeted user groups. Regional Dynamics Adoption of FeNO monitors varies by region, with the Americas benefiting from robust reimbursement frameworks and high asthma prevalence that promote device utilization. In Europe, Middle East & Africa, adoption ranges from well-established in Western countries to emerging uptake in Eastern and Middle Eastern regions. Asia-Pacific's demand is driven by urbanization and increasing respiratory diseases, necessitating tailored market entry strategies that consider regional regulatory environments and partnership networks. Competitive Landscape and Strategic Moves The competitive landscape for FeNO breathing monitors sees established corporations leveraging device-to-cloud integrations to solidify market positions, while newcomers emphasize affordability and usability. Strategic moves include partnerships with electronic health record vendors and acquiring technology startups to bolster service offerings. Aligning products with customer pain points is essential for achieving competitive advantage and market leadership. Conclusion FeNO breathing monitors are at the forefront of respiratory care innovation, enhancing the measurement of airway inflammation and integrating deeply into clinical practice. As the market evolves, stakeholders must navigate technological advances, regulatory changes, and global trade dynamics to capitalize on growth opportunities. Implementing agile sourcing strategies, fostering key opinion leader partnerships, and prioritizing interoperability within digital health ecosystems are critical for maintaining leadership in this rapidly developing field. Key Attributes: Report Attribute Details No. of Pages 189 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $303.1 Million Forecasted Market Value (USD) by 2030 $490.87 Million Compound Annual Growth Rate 10.0% Regions Covered Global Key Topics Covered: 1. Preface2. Research Methodology3. Executive Summary4. Market Overview5. Market Dynamics5.1. Rising demand for portable and user-friendly FeNO breath analysis devices5.2. Expansion of FeNO breath monitors into emerging markets and remote areas5.3. Role of AI and machine learning in improving FeNO device diagnostics5.4. Trends in insurance reimbursement policies supporting FeNO device usage5.5. Advancements in FeNO technology enhancing asthma management accuracy and ease5.6. Influence of regulatory approvals accelerating FeNO device market expansion5.7. Impact of telehealth integration on the adoption of FeNO breathing monitors5.8. Growth of personalized treatment plans driven by FeNO monitoring data5.9. Increasing awareness about respiratory health boosting FeNO monitor sales5.10. Collaborations between healthcare providers and tech firms for FeNO innovation6. Market Insights6.1. Porter's Five Forces Analysis6.2. PESTLE Analysis7. Cumulative Impact of United States Tariffs 20257.1. Comprehensive overview of major United States tariffs affecting the FeNO Breathing Monitor market from 2023 to 20257.2. Historical analysis and underlying economic rationale behind United States tariff policies affecting developed and developing countries from 2018 to 20257.3. Detailed analysis of the direct inflationary effects triggered by recent United States tariff implementations on the global economy7.4. Examination of reciprocal tariff dynamics and resultant trade wars between the United States and major global trading regions within a broader geopolitical framework7.5. Evaluation of the immediate and long-term economic and political impacts of United States tariffs on key international trading partners7.6. Identification of structural transformations in the United States economy driven by tariff-induced supply chain shifts and altered consumer purchasing behaviors7.7. Proposed policy measures and strategic approaches to alleviate the negative impacts of tariffs on the United States and its global trading partners8. FeNO Breathing Monitors Market, by Technology8.1. Introduction8.2. Chemiluminescence Sensors8.3. Electrochemical Sensors9. FeNO Breathing Monitors Market, by Patient Age Group9.1. Introduction9.2. Adults9.3. Geriatrics9.4. Pediatrics9.4.1. Infant9.4.2. Toddler10. FeNO Breathing Monitors Market, by Warning Signal10.1. Introduction10.2. Beep10.3. Light11. FeNO Breathing Monitors Market, by Distribution Channel11.1. Introduction11.2. Offline11.3. Online11.3.1. Brand Websites11.3.2. eCommerce Platforms12. FeNO Breathing Monitors Market, by Application12.1. Introduction12.2. Allergic Rhinitis12.3. Asthma Management12.3.1. Acute Asthma12.3.2. Chronic Asthma12.4. Chronic Obstructive Pulmonary Disease (COPD)12.5. Respiratory Distress Monitoring13. FeNO Breathing Monitors Market, by End User13.1. Introduction13.2. Ambulatory Care Settings13.3. Homecare Settings13.4. Hospitals & Clinics13.5. Research Laboratories14. Americas FeNO Breathing Monitors Market15. Europe, Middle East & Africa FeNO Breathing Monitors Market16. Asia-Pacific FeNO Breathing Monitors Market17. Competitive Landscape17.1. Market Share Analysis, 202417.2. FPNV Positioning Matrix, 202417.3. Competitive Analysis Bedfont Scientific Ltd. Bosch Healthcare Solutions GmbH CAIRE Inc. COSMED srl e-LinkCare Meditech Co.,Ltd. ECO MEDICS AG MGC Diagnostics Corporation NIOX Group plc Vitalograph Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment FeNO Breathing Monitors Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
3 days ago
- General
- New York Times
Five Things to Know About Assisted Dying in Canada
In 2023, one out of 20 Canadians who died received a physician-assisted death, making Canada the No. 1 provider of medical assistance in dying (MAID) in the world, when measured in total figures. In one province, Quebec, there were more MAID deaths per capita than anywhere else. Canadians, by and large, have been supportive of this trend. A 2022 poll showed that a stunning 86 percent of Canadians supported MAID's legalization. But in some corners, MAID has been the subject of a growing unease. While MAID in Canada was initially restricted to patients with terminal conditions — people whose natural deaths were 'reasonably foreseeable' — the law was controversially amended in 2021 to include people who were suffering but who weren't actually dying: patients who might have many years or even decades of life ahead of them. This new category includes people with chronic pain and physical disabilities. For The New York Times Magazine, I interviewed dozens of clinicians, ethicists, lawyers, advocates and patients about how MAID in Canada works. Here is what I learned: The criteria for MAID in Canada is among the broadest in the world When Canada's first MAID law, Bill C-14, passed in 2016, it had strict eligibility criteria: Patients needed to be over 18, eligible for Canadian health care and mentally competent to consent to death. They needed to have a 'serious and incurable illness, disease or disability'; be in an 'advanced state of irreversible decline in capability'; and have 'enduring physical or psychological suffering' that was 'intolerable.' Their natural deaths also had to be 'reasonably foreseeable.' In other words, they had to be dying. Early MAID patients were often people in their 70s or 80s with terminal cancer. In 2021, the Canadian government passed Bill C-7, which removed the criteria that a patient's death be 'reasonably foreseeable.' Now Canadians who are chronically sick or disabled — with conditions ranging from quadriplegia to multiple sclerosis to blindness to early-stage Parkinson's to chronic back pain — can receive assisted deaths from doctors or nurse practitioners. Within Canada, this newer kind of MAID is known as Track 2. Track 2 is controversial, even among MAID supporters Some clinicians who are involved with MAID objected to the legal expansion. They argue that it isn't really 'assistance in dying' if the patient isn't dying. Want all of The Times? Subscribe.
Yahoo
3 days ago
- General
- Yahoo
Carlisle GP surgery changes way patients book appointments to 'improve access'
A Carlisle GP surgery is changing the way patients book appointments to 'improve access'. As part of a new system called 'total triage', Eden Medical Group patients will now complete a questionnaire via the practice's website to book an appointment. Some patients will then be directed to a suitable local service such as pharmacies, but most patients will have their questionnaire reviewed by a clinician. The surgery triage team will review each patient request. The clinical team will decide what the most appropriate care for the patient is which includes deciding on the type of appointment for the patient. Triage requests are reviewed by clinical priority and the surgery will aim to respond to all requests within three working days, dealing with the most clinically unwell as a priority. The surgery said that the new system will 'improve access' to the practice, 'enhance the quality of care' and ensure patients are given the most appropriate appointment or advice to meet their needs, 'in a timely way'. For those unable to fill in the online form, the receptionist can take patients through the form in person or over the phone, they added.
Yahoo
6 days ago
- Business
- Yahoo
Eden Expands Metabolic Health Access Services with NAD⁺ via Injections, Patch, and Nasal-Spray Formats
Three clinician-guided options offer flexible, non-oral delivery paths for adults exploring NAD⁺ as part of their wellness routines. DENVER, May 29, 2025 /PRNewswire/ -- Eden, the leading health platform connecting individuals with independent licensed providers and pharmacies focused on metabolic health, today announced the nationwide availability of its NAD⁺ access program. The program includes subcutaneous injections, a once-weekly transdermal patch (Ionto STAT™), and a rapid-absorbing nasal spray. These options give adults new ways to consult with clinicians about whether NAD⁺ may complement their health and wellness goals. Nicotinamide adenine dinucleotide (NAD⁺) is a coenzyme found in all living cells that plays a role in cellular metabolism. Scientific literature suggests that NAD⁺ contributes to essential biological functions, including mitochondrial energy production, DNA repair, and cellular stress responses. NAD⁺ levels are known to decline with age, sparking growing interest in its potential role in aging-related cellular processes. Through Eden's platform, adults in all 50 states can access clinician consultations to determine if NAD⁺ is appropriate for their individual needs. Provider-guided protocols may include non-oral formats that are intended to support general wellness, particularly cellular functions related to metabolism and healthy aging. These offerings are available through licensed providers and compounding pharmacies, and are not approved by the FDA for any disease-specific use. "Many people are exploring NAD⁺ as a supplement to support cellular processes associated with energy metabolism and aging," said Adam McBride, CEO and co-founder of Eden. "Our platform ensures this exploration happens under clinician supervision, with flexibility and accountability." "We believe access and accountability go hand in hand," said Josh Khan, president and co-founder of Eden. "Our network partner providers set realistic expectations. While some individuals may report subjective improvements over time, outcomes vary widely and depend on many personal and clinical factors. Providers monitor patient response and adjust protocols based on evolving research and patient goals." Monthly plans begin at $119, terms apply. Existing Eden members can discuss NAD⁺ options during routine check-ins. Learn more at About Eden Eden is a health company that connects individuals with licensed doctors, compounding pharmacies, and nutrition solutions designed to support metabolic health. Through a seamless online experience, Eden helps patients explore personalized treatment options, offering a convenient approach to overall wellness support. Disclaimer: NAD⁺ formulations accessed through Eden's network are available via licensed healthcare providers and compounding pharmacies. These compounds are not approved by the Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease. Individual results may vary. These statements have not been evaluated by the FDA. View original content to download multimedia: SOURCE Eden Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
